Unmasking the cost of cancer drug development

Cancer drug R&D spending may be a fraction of the estimate cited by the biopharmaceutical industry. The average price of anticancer drugs has been rising by about 10 percent annually in...

Old cancer drugs, spendy new prices

Prices of older cancer drugs are rising much more steeply than those of newer drugs, according to a study co-authored by an OHSU oncologist. Using Medicare data available for Part B, the...